Fierce Pharma raises concerns about the FDA's ability to ensure drug safety, especially from foreign manufacturers, due to disruptions caused by the COVID-19 pandemic. The CEO of Valisure testified about flaws in the FDA's inspection process, emphasizing potential risks to the U.S. drug supply. This comes after the FDA requested recalls of metformin products from five manufacturers due to carcinogen contamination, a discovery made by Valisure. David Light urged senators to consider independent laboratory testing for all foreign-imported drugs to ensure transparency and address structural issues in the FDA's testing policies.
View the full article via Fierce Pharma.
Fierce Pharma raises concerns about the FDA's ability to ensure drug safety, especially from foreign manufacturers, due to disruptions caused by the COVID-19 pandemic. The CEO of Valisure testified about flaws in the FDA's inspection process, emphasizing potential risks to the U.S. drug supply. This comes after the FDA requested recalls of metformin products from five manufacturers due to carcinogen contamination, a discovery made by Valisure. David Light urged senators to consider independent laboratory testing for all foreign-imported drugs to ensure transparency and address structural issues in the FDA's testing policies.
View the full article via Fierce Pharma.
Fierce Pharma raises concerns about the FDA's ability to ensure drug safety, especially from foreign manufacturers, due to disruptions caused by the COVID-19 pandemic. The CEO of Valisure testified about flaws in the FDA's inspection process, emphasizing potential risks to the U.S. drug supply. This comes after the FDA requested recalls of metformin products from five manufacturers due to carcinogen contamination, a discovery made by Valisure. David Light urged senators to consider independent laboratory testing for all foreign-imported drugs to ensure transparency and address structural issues in the FDA's testing policies.
View the full article via Fierce Pharma.
Fierce Pharma raises concerns about the FDA's ability to ensure drug safety, especially from foreign manufacturers, due to disruptions caused by the COVID-19 pandemic. The CEO of Valisure testified about flaws in the FDA's inspection process, emphasizing potential risks to the U.S. drug supply. This comes after the FDA requested recalls of metformin products from five manufacturers due to carcinogen contamination, a discovery made by Valisure. David Light urged senators to consider independent laboratory testing for all foreign-imported drugs to ensure transparency and address structural issues in the FDA's testing policies.
View the full article via Fierce Pharma.